Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00298753
Status:
WITHDRAWN
Last Update Posted:
2015-09-15
First Post:
2006-03-01
Brief Title:
Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine
Sponsor:
Regional Hospital Holstebro
Organization:
Regional Hospital Holstebro
Study Overview
Official Title:
Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine
Status:
WITHDRAWN
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
no patients could be recruited
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients treated with the antiepileptic drug Oxcarbazepine often develop syndrome of inappropriate secretion of antidiuretic hormoneSIADHWe want to test the hypothesis that these patients have a higher reabsorption of water during the Aquaporine2 water channelsa higher concentration of Vasopressine AVP and a lower clearance of waterThis situation will tend to normalize when the patients are treated with fluid restriction
Detailed Description:
The purpose of the study is to determine the amount of Aquaporine2AQP2in the urine in patients treated with the antiepileptic drug Oxcarbazepine before and after the administration of fluid restriction
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None